Literature DB >> 28280090

Pooled Clustering of High-Grade Serous Ovarian Cancer Gene Expression Leads to Novel Consensus Subtypes Associated with Survival and Surgical Outcomes.

Chen Wang1, Sebastian M Armasu1, Kimberly R Kalli2, Matthew J Maurer1, Ethan P Heinzen1, Gary L Keeney3, William A Cliby4, Ann L Oberg1, Scott H Kaufmann2, Ellen L Goode5.   

Abstract

Purpose: Here we assess whether molecular subtyping identifies biological features of tumors that correlate with survival and surgical outcomes of high-grade serous ovarian cancer (HGSOC).Experimental Design: Consensus clustering of pooled mRNA expression data from over 2,000 HGSOC cases was used to define molecular subtypes of HGSOCs. This de novo classification scheme was then applied to 381 Mayo Clinic HGSOC patients with detailed survival and surgical outcome information.
Results: Five molecular subtypes of HGSOC were identified. In the pooled dataset, three subtypes were largely concordant with prior studies describing proliferative, mesenchymal, and immunoreactive tumors (concordance > 70%), and the group of tumors previously described as differentiated type was segregated into two new types, one of which (anti-mesenchymal) had downregulation of genes that were typically upregulated in the mesenchymal subtype. Molecular subtypes were significantly associated with overall survival (P < 0.001) and with rate of optimal surgical debulking (≤1 cm, P = 1.9E-4) in the pooled dataset. Among stage III-C or IV Mayo Clinic patients, molecular subtypes were also significantly associated with overall survival (P = 0.001), as well as rate of complete surgical debulking (no residual disease; 16% in mesenchymal tumors compared with >28% in other subtypes; P = 0.02).Conclusions: HGSOC tumors may be categorized into five molecular subtypes that associate with overall survival and the extent of residual disease following debulking surgery. Because mesenchymal tumors may have features that were associated with less favorable surgical outcome, molecular subtyping may have future utility in guiding neoadjuvant treatment decisions for women with HGSOC. Clin Cancer Res; 23(15); 4077-85. ©2017 AACR. ©2017 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28280090      PMCID: PMC5567822          DOI: 10.1158/1078-0432.CCR-17-0246

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  43 in total

1.  Adjusting batch effects in microarray expression data using empirical Bayes methods.

Authors:  W Evan Johnson; Cheng Li; Ariel Rabinovic
Journal:  Biostatistics       Date:  2006-04-21       Impact factor: 5.899

2.  Molecular biomarkers of residual disease after surgical debulking of high-grade serous ovarian cancer.

Authors:  Susan L Tucker; Kshipra Gharpure; Shelley M Herbrich; Anna K Unruh; Alpa M Nick; Erin K Crane; Robert L Coleman; Jamie Guenthoer; Heather J Dalton; Sherry Y Wu; Rajesha Rupaimoole; Gabriel Lopez-Berestein; Bulent Ozpolat; Cristina Ivan; Wei Hu; Keith A Baggerly; Anil K Sood
Journal:  Clin Cancer Res       Date:  2014-04-22       Impact factor: 12.531

3.  TGF-β modulates ovarian cancer invasion by upregulating CAF-derived versican in the tumor microenvironment.

Authors:  Tsz-Lun Yeung; Cecilia S Leung; Kwong-Kwok Wong; Goli Samimi; Melissa S Thompson; Jinsong Liu; Tarrik M Zaid; Sue Ghosh; Michael J Birrer; Samuel C Mok
Journal:  Cancer Res       Date:  2013-07-03       Impact factor: 12.701

Review 4.  A framework for a personalized surgical approach to ovarian cancer.

Authors:  Alpa M Nick; Robert L Coleman; Pedro T Ramirez; Anil K Sood
Journal:  Nat Rev Clin Oncol       Date:  2015-02-24       Impact factor: 66.675

5.  A collagen-remodeling gene signature regulated by TGF-β signaling is associated with metastasis and poor survival in serous ovarian cancer.

Authors:  Dong-Joo Cheon; Yunguang Tong; Myung-Shin Sim; Judy Dering; Dror Berel; Xiaojiang Cui; Jenny Lester; Jessica A Beach; Mourad Tighiouart; Ann E Walts; Beth Y Karlan; Sandra Orsulic
Journal:  Clin Cancer Res       Date:  2013-11-11       Impact factor: 12.531

6.  Relationship among surgical complexity, short-term morbidity, and overall survival in primary surgery for advanced ovarian cancer.

Authors:  Giovanni D Aletti; Sean C Dowdy; Karl C Podratz; William A Cliby
Journal:  Am J Obstet Gynecol       Date:  2007-12       Impact factor: 8.661

7.  Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval.

Authors:  Peter C Fong; Timothy A Yap; David S Boss; Craig P Carden; Marja Mergui-Roelvink; Charlie Gourley; Jacques De Greve; Jan Lubinski; Susan Shanley; Christina Messiou; Roger A'Hern; Andrew Tutt; Alan Ashworth; John Stone; James Carmichael; Jan H M Schellens; Johann S de Bono; Stan B Kaye
Journal:  J Clin Oncol       Date:  2010-04-20       Impact factor: 44.544

8.  Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer.

Authors:  V Abkevich; K M Timms; B T Hennessy; J Potter; M S Carey; L A Meyer; K Smith-McCune; R Broaddus; K H Lu; J Chen; T V Tran; D Williams; D Iliev; S Jammulapati; L M FitzGerald; T Krivak; J A DeLoia; A Gutin; G B Mills; J S Lanchbury
Journal:  Br J Cancer       Date:  2012-10-09       Impact factor: 7.640

9.  Strategies for aggregating gene expression data: the collapseRows R function.

Authors:  Jeremy A Miller; Chaochao Cai; Peter Langfelder; Daniel H Geschwind; Sunil M Kurian; Daniel R Salomon; Steve Horvath
Journal:  BMC Bioinformatics       Date:  2011-08-04       Impact factor: 3.169

10.  The MyD88+ phenotype is an adverse prognostic factor in epithelial ovarian cancer.

Authors:  Charles J d'Adhemar; Cathy D Spillane; Michael F Gallagher; Mark Bates; Katie M Costello; Jacqui Barry-O'Crowley; Kathryn Haley; Niamh Kernan; Ciara Murphy; Paul C Smyth; Ken O'Byrne; Stephen Pennington; Aoife A Cooke; Brendan Ffrench; Cara M Martin; Dearbhaile O'Donnell; Bryan Hennessy; Britta Stordal; Stephen Finn; Amanda McCann; Noreen Gleeson; Tom D'Arcy; Brian Flood; Luke A J O'Neill; Orla Sheils; Sharon O'Toole; John J O'Leary
Journal:  PLoS One       Date:  2014-06-30       Impact factor: 3.240

View more
  32 in total

1.  Cancer-associated stroma significantly contributes to the mesenchymal subtype signature of serous ovarian cancer.

Authors:  Qing Zhang; Chen Wang; William A Cliby
Journal:  Gynecol Oncol       Date:  2018-11-15       Impact factor: 5.482

2.  Factors that influence survival in high-grade serous ovarian cancer: A complex relationship between molecular subtype, disease dissemination, and operability.

Authors:  Diogo Torres; Chen Wang; Amanika Kumar; Jamie N Bakkum-Gamez; Amy L Weaver; Michaela E McGree; Gottfried E Konecny; Ellen L Goode; William A Cliby
Journal:  Gynecol Oncol       Date:  2018-06-18       Impact factor: 5.482

3.  Functional network community detection can disaggregate and filter multiple underlying pathways in enrichment analyses.

Authors:  Lia X Harrington; Gregory P Way; Jennifer A Doherty; Casey S Greene
Journal:  Pac Symp Biocomput       Date:  2018

Review 4.  Current Gaps in Ovarian Cancer Epidemiology: The Need for New Population-Based Research.

Authors:  Jennifer A Doherty; Allan Jensen; Linda E Kelemen; Celeste L Pearce; Elizabeth Poole; Joellen M Schildkraut; Kathryn L Terry; Shelley S Tworoger; Penelope M Webb; Nicolas Wentzensen
Journal:  J Natl Cancer Inst       Date:  2017-10-01       Impact factor: 13.506

Review 5.  Ovarian Cancers: Genetic Abnormalities, Tumor Heterogeneity and Progression, Clonal Evolution and Cancer Stem Cells.

Authors:  Ugo Testa; Eleonora Petrucci; Luca Pasquini; Germana Castelli; Elvira Pelosi
Journal:  Medicines (Basel)       Date:  2018-02-01

6.  Intraperitoneal disease dissemination patterns are associated with residual disease, extent of surgery, and molecular subtypes in advanced ovarian cancer.

Authors:  Diogo Torres; Amanika Kumar; Sumer K Wallace; Jamie N Bakkum-Gamez; Gottfried E Konecny; Amy L Weaver; Michaela E McGree; Ellen L Goode; William A Cliby; Chen Wang
Journal:  Gynecol Oncol       Date:  2017-09-28       Impact factor: 5.482

7.  Genes associated with bowel metastases in ovarian cancer.

Authors:  Andrea Mariani; Chen Wang; Ann L Oberg; Shaun M Riska; Michelle Torres; Joseph Kumka; Francesco Multinu; Gunisha Sagar; Debarshi Roy; Deok-Beom Jung; Qing Zhang; Tommaso Grassi; Daniel W Visscher; Vatsal P Patel; Ling Jin; Julie K Staub; William A Cliby; Saravut J Weroha; Kimberly R Kalli; Lynn C Hartmann; Scott H Kaufmann; Ellen L Goode; Viji Shridhar
Journal:  Gynecol Oncol       Date:  2019-06-14       Impact factor: 5.482

8.  Challenges and Opportunities in Studying the Epidemiology of Ovarian Cancer Subtypes.

Authors:  Jennifer Anne Doherty; Lauren Cole Peres; Chen Wang; Gregory P Way; Casey S Greene; Joellen M Schildkraut
Journal:  Curr Epidemiol Rep       Date:  2017-07-10

9.  Molecular characterization of high-grade serous ovarian cancers occurring in younger and older women.

Authors:  Olga T Filippova; Pier Selenica; Fresia Pareja; Mahsa Vahdatinia; Yingjie Zhu; Xin Pei; Nadeem Riaz; Kara Long Roche; Dennis S Chi; Nadeem R Abu-Rustum; Lora H Ellenson; Jorge S Reis-Filho; Dmitriy Zamarin; Britta Weigelt
Journal:  Gynecol Oncol       Date:  2021-03-03       Impact factor: 5.482

10.  Semi-Supervised Topological Analysis for Elucidating Hidden Structures in High-Dimensional Transcriptome Datasets.

Authors:  Tianshu Feng; Jaime I Davila; Yuanhang Liu; Sangdi Lin; Shuai Huang; Chen Wang
Journal:  IEEE/ACM Trans Comput Biol Bioinform       Date:  2021-08-06       Impact factor: 3.710

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.